Snapshot from Jun 09, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Protagenic Therapeutics Engages...
Business strategic engagement

Protagenic Therapeutics Engages Regulatory, Operations Advisors

Analysis based on 6 articles · First reported May 19, 2026 · Last updated May 19, 2026

Sentiment
60
Attention
3
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The engagements are expected to accelerate the development of PT-00114, potentially increasing the market value of AnBogen Therapeutics. The strengthened operational and regulatory framework could attract further investment in AnBogen Therapeutics.

biopharmaceutical consulting
Event Summary

AnBogen Therapeutics, a clinical-stage biopharmaceutical company, announced two strategic engagements to advance its lead candidate, PT-00114, a neuropeptide for stress-related neuropsychiatric disorders. The company engaged Floyd Regulatory Strategic Consulting, led by Dr. Eric Floyd, as Regulatory Affairs Advisor to guide PT-00114's regulatory strategy, including IND maintenance and Phase 2 submission planning. Additionally, AnBogen Therapeutics partnered with Danforth Health, a life science operational consulting firm, to establish robust operational processes and infrastructure. These engagements, coupled with the recent separation of Phytanix which improved AnBogen Therapeutics' balance sheet, position the company to advance PT-00114 into Phase 2 clinical studies in 2026.

Key Actions
90 AnBogen Therapeutics engaged Floyd Regulatory Strategic Consulting
90 AnBogen Therapeutics engaged Danforth Health
70 AnBogen Therapeutics completed separation Phytanix
Entities Involved
priv
AnBogen Therapeutics
AnBogen Therapeutics engaged two consulting firms to advance its lead candidate, PT-00114, into Phase 2 clinical studies, which is expected to strengthen its operational processes and regulatory strategy.
Importance 100 Sentiment 70
oth
PT-00114
PT-00114 is AnBogen Therapeutics' lead clinical asset, a neuropeptide targeting stress-related neuropsychiatric disorders, which is being advanced into Phase 2 clinical studies with the support of the new engagements.
Importance 90 Sentiment 60
priv
Floyd Regulatory Strategic Consulting
Floyd Regulatory Strategic Consulting was engaged by AnBogen Therapeutics to provide regulatory affairs advisory services for PT-00114, leveraging its expertise in CNS drug development.
Importance 80 Sentiment 60
priv
Danforth Health
Danforth Health was engaged by AnBogen Therapeutics to establish institutional-grade operational processes and infrastructure, providing flexible and scalable support for the company's growth.
Importance 80 Sentiment 60
per
Eric Floyd
Dr. Eric Floyd, founder of Floyd Regulatory Strategic Consulting, will lead AnBogen Therapeutics' regulatory strategy for PT-00114, bringing over 25 years of experience in the pharmaceutical industry.
Importance 70 Sentiment 60
per
Bill Nichols Jr.
Bill Nichols Jr., President of AnBogen Therapeutics, expressed confidence in the strategic engagements, highlighting the expertise of Dr. Eric Floyd and the capabilities of Danforth Health.
Importance 40 Sentiment 50
oth
Phytanix
The separation of Phytanix in March 2026 strengthened AnBogen Therapeutics' balance sheet by removing liabilities and reducing annualized costs, contributing to its readiness for PT-00114's Phase 2 advancement.
Importance 20 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.